etude 2012-vinteractive francebiotech
TRANSCRIPT
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
1/35
Sindrili df tgo Fronbg
@hfo Rbhonbos Hneustry=39=
99tg Oehthdn
b
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
2/35
Oehtdrhi`
go @hfo Rbhonbos sob
tdr gis tdeiy mobdlo
i lirjot roi`hty, ropro
sonthnk i rosorvdhr df hnndvi
thdn ine krdwtg. Hneooe, ht hs
ehffhbu`t td fu``y onvhshdn tgo
sbdpo df hlpibt tgit tgo @hfo
Rbhonbos wh`` mrhnk td dur hvos
dvor tgo noxt =3 yoirs. Hn
Frinbo, eosphto tgo brhshs, tghs
hneustry gis prdkrossoe shknh
fhbint`y dvor tgo pist 9? yoirs
ine gis roibgoe i stiko df
liturhty tgit hs rof`obtoe hn
tgo rosu`ts df dur stuey.
Frinbo Mhdtobg gis moon it
tgo fdrofrdnt df tghs olor
konbo df @hfo Rbhonbos hn
Frinbo, suppdrthnk tgo krdwtg
df in hneustry tgit hnb`ueos
mhdtobg, loetobg ine b`oin
tobg bdlpinhos. My wiy df
dur liny bdnstrubthvo prdpd
si`s ine robdlloneithdns
eo`hvoroe td tgo kdvornlont,wo givo go`poe konorito i
eynilhb sobtdr hn wghbg ro
soirbg ine eovo`dplont iro
tgo erhvhnk fdrbos df obdnd
lhb krdwtg ine, is i bdnso
quonbo, df oxpdrts.
Ugo @hfo Rbhonbos hneustry hn
Frinbo ehsthnkuhsgos htso`f my
i eynilhb fhninbhi` lirjot
tgit hnvosts hn, ini`yzos ine
suppdrts hts sustihnim`o eo
vo`dplont. Ugo liny ydunk
bdlpinhos tgit lijo up tghs
sobtdr bdlmhno td litbg i
`irko pgirlibouthbi` bdl
piny hn liny loisuros, whtg
tgo ieehthdni` bipibhty fdr
eovo`dphnk ehsrupthvo tobgnd
`dkhos ine tijhnk rhsjs.
Ugo nirrdw prhsl tgrdukg
wghbg dur pum`hb iutgdrhthos
ine hneustry `oieors soo dur
ydunk hnndvithvo bdlpinhos
tihnts tgo eovo`dplont df dur
`oieors df tdldrrdw. Rli``
ine lheshzo ontorprhsos
'SLOs( iro sth`` dn`y soon is
i supp`hor dr sumbdntribtdr
fdr i `irko krdup. Ht hs thlo tdrobdknhzo tgo guko pdtonthi`
tgit rosheos hn dur sli`` hn
ndvithvo bdlpinhos. Ht hs thlo
td put hn p`ibo tgo nobossiry
`okhs`ithvo loisuros td fur
tgor onbduriko tgohr krdwtg.
Adms, oxpdrts ine obdndlhb
krdwtg wh`` fd``dw ine tgo
monofht wh`` mo bd``obthvo.
Fhni``y, H wdu`e strdnk`y wirn
dur `oieors df tgo einkor
pdsoe my Frinbos toneonby
td b`hp subbossfu` prdkrils
ine sprhnj`o pdpu`hst loi
suros hntd `okhs`ituro. Rubg
ibthdns rhsj hlldmh`hzhnk tgo
obdndly ine bin hneubo eo
b`hno. [o nooe i pd`hthbi` wh``
tgit hs fdbusoe dn suppdrthnk
dur phdnoorhnk ydunk bdlpi
nhos ine prdtobthnk tgol hn
tgo hntornithdni` ironi.
Iner Bgdu`hji
Iner Bgdu`hjiSrosheont df Frinbo Mhdtobg,Bgihrlin ine BOD df Bo``obths
U
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
3/35
Lotgded`dky
Sirt df tgo ini`yshs prosontoe hn tghs stuey hs misoe dn eiti
bd``obtoe frdl Fronbg @hfo Rbhonbos bdlpinhos vhi i soburo
dn`hno survoy p`itfdrl.
Hn dreor td tijo pirt hn tgo survoy, i bdlpiny lust loot tgo
fd``dwhnk tgroo brhtorhi1
` Mo ibthvo hn tgo @hfo Rbhonbos hneustry hn Frinbo
I``dbito it oist 9?/ df tdti` oxponsos td ]osoirbg
ine Eovo`dplont
` Givo `oss tgin =?3 olp`dyoos
[gh`o tgo @hfo Rbhonbos sobtdr hn Frinbo gis fdr liny yoirs
moon edlhnitoe my Sothto ot Ldyonno Ontroprhsos , tghs
yoir siw tgo hnb`ushdn df tgroo bdlpinhos tgit robont`y
krieuitoe frdl Sothto ot Ldyonno Ontroprhsos stitus td
Ontroprhsos eo Uih``o Hntorlehihro stitus. Ugo tgrosgd`e df
]&E hnvostlont rolihns it 9?/ df tdti` oxponsos, tgo silo
`ovo` roquhroe td kihn o`hkhmh`hty fdr tgo Xdunk Hnndvithvo
Ontorprhso 'AOH( stitus hn Frinbo. Rhlh`ir td tgo =399 htorithdn,
tghs yoirs survoy p`iboe in ieeoe olpgishs dn tgo hnbdrpd
rithdn df i roprosontithvo silp`o df Loetobg ine B`ointobgbdlpinhos.
Ugo rosu`ts df tgo survoy givo moon pum`hsgoe hn ikkrokito
hn dreor td rospobt tgo bdnfheonthi`hty df rospdneonts.
Ugo bdnvonthdni` eofhnhthdn df Mhdtobgnd`dky iedptoe my tgo
DOBE hs Ugo ipp`hbithdn df sbhonbo ine tobgnd`dky td `hvhnk
drkinhsls, is wo`` is pirts, prdeubts ine ldeo`s tgorodf, td
i`tor `hvhnk dr ndn`hvhnk litorhi`s fdr tgo prdeubthdn df jndw
`oeko, kddes ine sorvhbos.
98= bdlpinhos eob`irhnk ibthvhthos hn tgo @hfo Rbhonbos
pirthbhpitoe hn tgo o`obtrdnhb survoy ielhnhstoroe vhi Rpghnx
sdftwiro frdl Fomruiry 95 td Iprh` 9? =392. ]ospdnsos frdl
976 bdlpinhos woro rotihnoe fdr ini`yshs ine hnb`ushdn hn
tgo Sindrili.
Fhninbhi` eiti ine hnfdrlithdn rokirehnk pum`hb pd`hby prd
krils woro bdlph`oe my Frinbo Mhdtobg stiff lolmors ushnk
pum`hb rosdurbos ine tghrepirty eitimisos.
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
4/35
Uim`o df Bdntonts
?
HNU]DE_BUHDN
Ghstdry df tgo Fronbg @hfo Rbhonbos Hneustry 36
Joy Fhkuros fdr =39= 37
Kodkripghbi` Ehstrhmuthdn 38
F]INBO1 MHDUOBG INE LOEUOBG IBUHVHUX
Bdlpiny Rhzo ine Olp`dyoo Oeubithdn 93
Bdlpiny Iko, Drhkhn ine Edlihn df Ibthvhty 99
Bdlpiny Broithdns ine @hquheithdns 9=Oxport tosthldny1 Sgh`hppo Sdu`otty, LE 92
Sirtnorsghps ine B`honts 95
Oxport tosthldny1 Sgh`hppo Kdupht 9?
Sitonts 96
Oxport tosthldny1 Li`ys Forroro 9;
Srdeubts 97
F]INBO1 FHNINBHNK HNNDVIUHDN
K`dmi` Sorspobthvo df Robtdr Funehnk =3
_so df Sum`hb Lirjots =9
Oxport tosthldny1 ]ifi`o Udrealin, LE ==
Vonturo Biphti` =2
Kdvornlont Ruppdrt =5
Oxport tosthldny1 Siu`Frindhs Fdurnhor =?
HNUO]NIUHDNI@ SO]RSOBUHVOR
@hfo Rbhonbos Bdlpinhos dn tgo NXRO Ourdnoxt$I`tornoxt =7NXRO NOWU Mhdtobg Hneox =8
Oxport tosthldny1 Berhb Ldroiu 23
Bdlpirhsdn df VB Fhninbhnk hn Ourdpoin @hfo Rbhonbos 29
INNOW
@hst df Bdllorbhi`hzoe Srdeubts ine Sum`hb Bdlpinhos 2=
@hst df 976 bdlpinhos pirthbhpithnk hn tgo stuey 22
Oxghmht Hneox 25
Imdut Frinbo Mhdtobg ine tgo Sindrili Rtuey 2?
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
5/35
6
HSD1 F`ilo` Uobgnd`dkhos 'Auno(
HSD1 Borop 'Fomruiry(:Urinskono 'Lirbg(:Rti``orkonos 'Au`y(
HSD1 Nhbdx 'Ndvolmor(
Fdunehnk df Frinbo Mhdtobg
Fdunehnk df @FM
Fdunehnk df Konsot
Fdunehnk df Biy`i
Fdunehnk dfUrinskono
Broithdn df tgo Ikonbo Nithdni`o eo i]obgorbgo 'IN](!:Broithdn df DROD:Broithdn df tgo Bdlpoththvhty MhdB`ustors
Broithdn df HnndMhd, tgo spobhi`ty hnvostlontfune fdr Mhdtobg linikoe my BEB Ontroprhsos
Broithdn df tgo Xdunk Hnndvithvo Bdlpiny 'AOH(eoshknithdn!
98;;
98;8
9885
9872
9878
=335
9888
9887
988;
9886
=336
=33;
=337
=338
=33?
Ghstdry df tgo Fronbg @hfo Rbhonbos Hneustry
Broithdn df tgo ]osoirbgUix Broeht 'BH](
Xoir
98;;
9873
987=
9875
987;
9878
=33=
Konsot 'F]( purbgisoe my Rordnd 'BG(
Sisshnk df tgo UOSI @iw!'Iukust =33;(
!robdlloneoe my Frinbo Mhdtobg
Broithdn df tgo NXRO Ourdnoxt NOWU Mhdtobg Hneox!:Broithdn df tgo Rtritokhb Hnvostlont Fune 'FRH(:Broithdn df tgo Rtritokhb Hneustrhi` Hnndvithdn'HRH( fune it DROD!
Sisshnk df tgo Hnndvithdn @iw 'Au`y 9888(, `oiehnk tdtgo broithdn df tgo Bdnbdurs Nithdni` eIheo `iBrithdn eOntroprhsos eo Uobgnd`dkhos Hnndvintos
Broithdn df tgo Nduvoiu Lirbg stdbj oxbginko fdr stirtup bdlpinhos
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
6/35
9
;
=393
=392Broithdn df mphfrinbo, tgo Fronbgpum`hb minj df hnvostlont
ILL hssuoe td MhdI``hinbo Sgirli fdr RhtivhkHSD1 Rphnowiy 'Fomruiry(: Rphnokuire 'Iprh`(: Orytobg 'Iprh`(
Oxdnght 'F]( purbgisos HnKon Mhdsbhonbos 'F]( ine mobdlosEhixdnght: Vhvi`hs 'F]( purbgisos Hntorbo`` 'I_( ine mobdlosVi`novi: Ndviki`h Sgirli 'F]( hs purbgisoe my Rinton Sgirlibouthbi`s 'AS(
HSD1 Iedbhi 'Fomruiry(: ODR Hlikhnk 'Fomruiry(: Hntrisonso'Fomruiry(: EMV Uobgnd`dkhos 'Lirbg(: Nindmhdthx 'Dbtdmor(:Ndvibyt 'Dbtdmor(: Ugoriehik 'Eobolmor(
Rindfh 'F]( purbgisos Konzylo '_R(: Hpsdkon hs purbgisoemy Yhikon 'N@( ine mobdlos Yhikon Lirsoh``o: Bo``obths 'F](purbgisos Bo``irths 'RO(HSD1 Mhdsynox 'Lirbg(: Loehin Uobgnd`dkhos 'Liy(: K`dmi`Mhdonorkhos 'Auno(: Liuni Joi Uobgnd`dkhos 'Au`y(
Bo``obths 'F]( purbgisos BytdSu`so Rbhonbos '_R(HSD1 IM Rbhonbo 'Iprh`(: Eohndvo 'Iprh`(: Nodvibs 'Iprh`(:Hntokrikon 'Auno(: Birlit 'Au`y(: Rtontys 'Dbtdmor(
Rindfh 'F]( purbgisos Fdvoi Sgirlibouthbi`s 'F](:IstriQonobi '_J( purbgisos Ndvoxo` 'F](HSD1 Yuintul Kondlhbs 'Au`y(
HSD1 Hpsdkon 'Auno(
HSD1 Bo``obths 'Fomruiry(: Lotimd`hb Oxp`dror 'Iprh`(: Kondwiy 'Liy(:Vhvi`hs 'Auno(: Gymrhkonhbs 'Eobolmor(
ILL hssuoe td MhdI``hinbo Sgirli fdr @drilybHSD1 Hnnito Sgirli 'Lirbg(: Konfht 'Eobolmor(
HSD1 Oxdnght 'Ndvolmor(: MhdI``hinbo Sgirli 'Eobolmor(
=39=
Nulmor dfBdlpinhosFduneoe
9889
9882
988?
988;
9888
=339
=332
=33?
=33;
=338
=399
Ainuiry =399 1Eristhb ]ofdrl dftgo AOH eoshknithdn
=399
Ovd`uthdn df @hfo Rbhonbos Bdlpiny Broithdn hn Frinbo
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
7/35
Frinbo1 Joy Fhkuros fdr =39=
bdlpinhosstuehoe
df bdlpinhos iro93* yoirs d`e
bdlpinhosbroitoe hn =39=
tdti` olp`dyoos'ivk df == por
bdlpiny(
bdllorbhi`hzoetgoripouthb prdeubts tgoripouthb prdeubtshn eovo`dplont ehikndsthb prdeubtshn eovo`dplont loehbi eovhboshn eovo`dplont
pum`hb`y trieoebdlpinhos
hn tdti`rovonuos
hnvostoe hn ]osoirbgine Eovo`dplont
osthlitoenot `dssos
976 22/ 58 59?3
=? =78 78 98
26 =?9 L =87L =56L
7
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
8/35
8
H`o,eo,Frinbo
??
Mrotikno
;Siys eo`i @dhro
99
Sdhtdu,Bgirontos
9
Bontro
9 Mdurkdkno2
Bgilpikno,Ireonno
9
Shbireho
=
Ndre,Sis,
eo,Bi`ihs
Lheh,Syrnos
92
@inkuoedb,]dussh``dn
9?
Iquhtihno
2
MissoNdrlineho
]gno,I`pos
2?
@hldushn
? Iuvorkno
?
Frinbgo,Bdlt
9
@drrihno
=
Srdvonbo,I`pos,Bto eIzur
93
Bdrso
GiutoNdrlineho
Kodkripghbi` Ehstrhmuthdn
I`sibo
>< 5?
=2 5?
9= =2
0 9=
?
2
H`oeoFrinbo bdnthnuos td givo tgo ghkgost bdnbontrithdn df @hfo Rbhonbos bdlpinhos hn Frinbo, is i`ldst i
tghre df tgo bdlpinhos rospdnehnk td tgo survoy iro goiequirtoroe hn tgo rokhdn. Ugo ]gnoI`pos rokhdnrotihns hts pdshthdn is tgo sobdne irkost bontor df ibthvhty hn Frinbo. Ughs yoirs silp`o wis ehsthnkuhsgoe mystrdnk @hfo Rbhonbos roprosontithdn hn tgo sdutgorn rokhdns dfSIBI, @inkuoedb]dussh``dn ine LhehSyrnos.Ldst hlpdrtint`y, i goi`tgy ehstrhmuthdn df bdlpiny hlp`intithdn ibrdss tgo bduntry hs bdnfhrloe my tgo survoyrospdneonts. Ugo prosonbo df tgo MhdSd`o bdlpoththvhty b`ustors bdnthnuos td onbduriko rokhdni` ehvorshty.
Rdurbo1 Frinbo Mhdtobg Liy =392: 976 bdlpinhos
;
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
9/35
Rdurbo1 Frinbo Mhdtobg Liy =392: 976 bdlpinhos Rdurbo1 Frinbo Mhdtobg Liy =392: 9?3 bdlpinhos
Bdlpiny Rhzo ine Olp`dyoo Oeubithdn
Nulmor df olp`dyoos @ovo` df Oeubithdn Ibghovoe my Olp`dyoos
93
9 td ?
6 td 93
99 td 23
29 td 88
Listors
SgE
Mibgo`drs Eokroo
Ghkgsbgdd`
933*
=;/
5/
23/
=5/
96/
2?/
92/
=5/
=7/
= 2
Dur ini`yshs sgdws tgit bdlpinhos hn tgo @hfo Rbhonbos sobtdr rolihn, fdr tgo ldst pirt, sli`` strubturos
tgit drhkhnito frdl ibieolhb rosoirbg ine olp`dy ghkg`y oeubitoe wdrjors. Eosphto tgo robont`y stdrlyobdndlhb onvhrdnlont hn Ourdpo, tgo hneustry eoldnstritoe hts vorsith`hty hn =39= my rovorshnk tgonokithvo trone df not bdlpiny broithdn, wgh`o tgo liadrhty df survoy rospdneonts '?7/( ropdrtoe ipdshthvo dut`ddj ine nd ehffhbu`thos pdsoe my strubturi` hssuos. Ibthvhthos hn tghs sobtdr iro lihn`y fdbusoedn eovo`dphnk tgoripouthb, ehikndsthb ine loehbi` eovhbo prdeubts hn tgo edlihn df gulin goi`tg, muthn robont yoirs B`ointobg bdlpinhos givo bdnthnuoe td krdw hn nulmor ine shzo. Ugo phpo`hno df tgoripouthb prdeubt eovo`dplont rolihns rdmust whtg i`ldst983 prdkrils hn tgo prddf df bdnbopt dr prob`hnhbi` pgiso df eovo`dplont ine 2= prdeubts hn tgo lhest df Sgiso HH trhi`s.
Rhlh`ir td provhdus Sindrili stuehos, tgo liadrhty df bdlpinhos hn tghs yoirs pino` iro sli`` strubturos. ?;/
df bdlpinhos givo 93 dr fowor olp`dyoos, wgh`o dn`y sovon bdlpinhos givo ldro tgin 933 olp`dyoos.]obruhtlont hn tghs hnndvithvo sobtdr hs lihn`y fdbusoe dn hnehvheui`s whtg ievinboe eokroos, is 62/ dfolp`dyoos gd`e ohtgor i Listors dr SgE `ovo` eokroo. 59?3 podp`o hn tdti` iro olp`dyoe hn tghs hnndvithvo sobtdr,lijhnk in ivoriko df== podp`o por bdlpiny.
F]INBO1 MHDUOBG INE LOEUOBG IBUHVHUX
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
10/35
99
Bdlpiny Iko, Drhkhn ine Edlihn df Ibthvhty
Rdurbo1 Frinbo Mhdtobg Liy =392: 976 bdlpinhos Rdurbo1 Frinbo Mhdtobg Liy =392: 979 bdlpinhos
Drhkhn df tgo bdlpiny
27/
=8/ 22/93* yoirs
6 td 93 yoirs
3 td ? yoirs
8/
22/
?5/
Ibieolhb ]osoirbg
Rli`` Mushnoss Rtirtup
Dtgor
5/
Rphndff frdlmhk bdlpiny
Bdlpinhos my iko5 ?
Edlihn df Ibthvhty
Rdurbo1 Frinbo Mhdtobg, Liy =392: 976 bdlpinhos
6
Ugo liadrhty df Fronbg @hfo Rbhonbos bdlpinhos bdlo dut df tgo Ibieolhb sobtdr, fd` dwoe b`dso`y my sli``mushnoss ontropronours, wgh`o dn`y 5/ df tgo pino` drhkhnitoe is i sphndff frdl i mhk bdlpiny. Ughs yoirsrospdneonts prosont i goi`tgy ehstrhmuthdn hn torls df bdlpiny iko, sgdwhnk i rdukg`y ovon sp`ht motwoonstirtup stiko, krdwtg pgiso ine eovo`dpoe bdlpinhos. Ugo prdfh`o df tgo BODs hn dur survoy furtgor eoldnstritos tgo vhti`hty ine rosh`honbo df tgo ontropronourhi` sphrht hn tghs sobtdr1
59/ df BODs givo moon tgo BOD df indtgor bdlpiny
;;/ df BODs iro fduneors df tgohr bdlpiny;5/ df BODs iro sbhonthsts my trihnhnk
Gulin Goi`tg bdnthnuos td mo tgo ldst bdlldn edlihn df bdrpdrito ibthvhty ildnk tghs yoirs survoyrospdneonts. Inhli` Goi`tg ine Bdslothbs rolihn fdbus irois fdr liny bdlpinhos, wgh`o =39= siw inhnbroiso df ibthvhty hn tgo edlihn df Oquhplont & ]oikonts. @ddjhnk mrdie`y it B`ointobg ehsbhp`hnos, ibdlmhnoe 9=/ df ibthvhthos iro fdbusoe dn tgo Onvhrdnlonti`$Onorky, S`int Srdeubthdn ine Kroon Mhdtobgedlihns '93/ hn =399(.
Gulin
Goi`tg
95/
8/ 7/6/ ?/ ?/ 5/ 5/ 5/ 2/ 2/ 2/
53
3
=3
93
2329/
Inhl
i`Goi`tg
Oquhpl
ont
&]o
ikonts
Bdsl
othbs
Ikrh,fd
deGul
in
Onvhr
dnlont$On
orky
Loehbi
`Eovhbo
s
ineOq
uhpl
ont
Dtgo
r
Hnfdrl
ithdn
Uobgnd`dky
S`intS
rdeubthdn
Ikrh,fd
deInhli`
Nindto
bgnd`dky
KroonMh
dtobg
/
Ibthvhty
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
11/35
9=
Lorkors ine Ibquhshthdns=39= wis lirjoe my tgo inndunbolonts hn Eobolmor df twd liadr ibquhshthdns hn tgo Fronbg @hfo Rbhonbossobtdr. Ugo ehikndsthbs bdlpiny Oxdnght purbgisoe HnKon Mhdsbhonbos '98 L(, broithnk i now fu``y hntokritoe`oieor hn tgo fho`e df hnvhtrd ehikndsthbs my tgo nilo dfEhixdnght. Ughs wis fd``dwoe my tgo mhdpgirlibouthbi`bdlpinyVhvi`hs purbgiso df Iustrhin fhrl Hntorbo`` '922 L(, wghbg broitoe i now mhdtobg `oieor hn vibbhnosine inthmdehos my tgo nilo dfVi`novi RO. Dtgor L&I ibthvhty hnb`ueoe tgo purbgiso dfOb`it Sgirlibouthbi`smy F`ilo` Uobgnd`dkhos, tgo ibquhshthdn df mhdtobgnd`dky fhrl Srosthzhi my tgorindsthbs bdlpinyUgoriehikinetgo ibquhshthdn df ]&E fhrl Borop my Ourdfhns Ehsbdvory Rorvhbos.
Bdlpiny Broithdns ine @hquheithdns
5956
=5
5852
? 8
=3=?
95
=337 =338 =393 =399 =39=
Broithdns
@hquheithdns
=3
53
63
3
,=3
,53
Not
Nulmor
Xoir
;
Iftor strukk`hnk td broito now bdlpinhos hn =399, tgo @hfo Rbhonbos sobtdr sgdwoe hts eynilhsl hn =39= mykonorithnk i not broithdn df2? bdlpinhos. Ughs trone bdhnbheos whtg dnkdhnk rdmust ibthvhty hn Lorkors ineIbquhshthdns ine bdnfhrls tgo funeilonti` stronktg df hnndvithdn hn tgo @hfo Rbhonbos hn Frinbo tdeiy.
272=
=6
9
2?
F]INBO1 MHDUOBG INE LOEUOBG IBUHVHUX
Rdurbo1 Frinbo Mhdtobg Liy =392
Nulmor df bdlpinhoshn Sindrili
Olp`dyoos eob`iroe mySindrili rospdneonts
HSDs
=33;
Ovd`uthdn df Joy Hneustrhi` Hnehbitdrs
VB Funehnk 'L(
Lirjotoe prdeubts
Sum`hb Bdlpinhos
932
=337 =338 =393 =399 =39=
923 9;3 =99 983 976
2 65? ? 288 2 9;7 ? 26? 5 ==8 5 9?3
? 9 3 ; 6 7
979 =32 939 972 9=9 927
; 92 99 =3 == =?
9; =3 =9 =9 =7 26
Xoir
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
12/35
Oxport tosthldny
go shtuithdn hs hlprd
vhnk mut tgo sobtdr
nooes td bdnthnuo
td krdw, pirthbu`ir`y hn torls
df pum`hb`y trieoe bdlpinhos.
Ugoro iro tgroo bgi``onkos td
ieeross1 hntornithdni`hzithdn,
tgo spooe df tobgnd`dky trins
for ine tgo ivih`imh`hty df fhninbhnk. Frinbo `ibjs oxports
hn i`` tgroo irois ine nooes
spobhi hsts tgit iro bipim`o df
loisurhnk tgo truo vi`uo df
in heoi ine ro`ithnk ht td tgo
burront hneustry `inesbipo.
[o nooe td `iunbg now prd
aobts ldro quhbj`y wgh`o ro
lihnhnk pithont fdr tgol td
moir fruht.
Fhninbhnk hs tgo joy. Hnsthtuthdni` hnvostdrs iro tdd ro`ubtint
rhkgt ndw ine tgo vonturo bi
phti`hsts ibthvo hn tgo @hfo
Rbhonbos nulmor fir tdd fow.
Hts hlpdrtint td givo @hfo
Rbhonbos ontropronours, mut
givhnk i stim`o df pirtnors td
ibbdlpiny tgol tgrdukg oibg
pgiso df fhninbhnk, frdl sooe
td oxpinshdn, hs i`sd ossonthi`.
Linikolont orrdrs iro is ox
ponshvo is fhninbhi` rosdurbos
iro riro: bdlpinhos nooe tdeovo`dp i `dnk torl vhshdn
frdl tgo vory mokhnnhnk. Srd
aobts run my i linikolont
toil whtg eoop oxporthso hn
ehvorso fho`es ine in imh`hty td
sgrowe`y vi`uo tgohr hnto``ob
tui` prdporty wh`` givo tgo
most bginbo fdr subboss.
Ldro tgin inytghnk tgo li
nikolont toil nooes td mo
im`o td broehm`y rospdne tdtghs quosthdn1 hn wgit wiy iro
wo kdhnk td bginko pithonts
`hvos4
Sgh`hppo Sdu`otty
Sgh`hppo Sdu`otty, LEBdFduneor, BOD ine Goie df @hfo
Rbhonbos it Uruff`o Biphti`
Gdndriry Srosheont df Frinbo Mhdtobg
[o nooe td `iunbg now prdaobts ldro quhbj`y
U92
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
13/35
Ehstrhmuthdn df B`honts my Hneustry Robtdr
Sgirlibouthb
i`
Hneustry
98/
95/
8/7/
6/?/
5/ 5/ 5/ 5/2/
=3
=?
3
93
?
9?
==/
Mhdtobgn
d`dky
Sum`hb]o
soirbg
Goi`tg
biro
Fibh`hthos
Bdsl
othbHneustry
Loehbi
`Eovhbo
s
Ikrh,fd
deHneustry
Dtgo
r
Goi`tg
biro
Onvhr
dnlonti`
Bgol
hbi`Hneustry
Firlhnk$mr
ooehnk
95
/
8
Ugo sdurbo df rovonuos fdr ldst bdlpinhos hn tghs yoirs Sindrili stuey hs shlh`ir td robont yoirs, whtg tgoSgirlibouthbi` ine Mhdtobgnd`dky hneustrhos, is wo`` is Sum`hb ]osoirbg @imdritdrhos, rolihnhnk tgo ldstfroquont bustdlors fdr Fronbg @hfo Rbhonbo bdlpinhos. Hn fibt, ;7/ df rospdneonts ropdrtoe it `oist dnoSgirlibouthbi` hneustry b`hont ine ?3/ ropdrtoe it `oist dno Sum`hb ]osoirbg @imdritdry b`hont.
Sirtnorsghps ine stritokhb i``hinbos bdnthnuo td p`iy in hlpdrtint rd`o hn tgo Fronbg @hfo Rbhonbos hneustry. ?7/df tghs yoirs survoy rospdneonts ropdrtoe givhnk dno dr ldro pirtnorsghp hn p`ibo ine dvor533 tdti` pirtnorsghpsworo eob`iroe. Ugo fduneithdni` rd`o p`iyoe my tgo Fronbg ibieoly hn tgo @hfo Rbhonbos sobtdr sgdws up ikihnhn tghs edlihn, is noir`y gi`f '56/( df ropdrtoe pirtnorsghps woro bdnsthtutoe whtg ibieolhb rosoirbg hnsthtutos'hnb`uehnk BN]R, HNRO]L, Hnsthtut Sistour, Hnsthtut Burho ine ISGS(. Ugoso ro`ithdnsghps iro vory hntornithdni` hnnituro, is noir`y i tghre df pirtnors iro ndnFronbg drkinhzithdns. Furtgorldro, 9 dut df ovory ? Fronbg @hfoRbhonbos bdlpinhos whtg i pirtnorsghp gis eovo`dpoe in ibbdre whtg i k`dmi` Mhk Sgirli bdlpiny 'hnb`uehnkRindfh, K`ixdRlhtgJ`hno, Lorbj, Ndvirths, Ndvd Ndrehsj, Sfhzor, Rorvhor, UOVI, O`h @h``y ine Mrhstd`Lyors Rquhmm(,sgdwhnk tgit tgo bdnnobthdns whtg tgo pgirlibouthbi` hneustry rolihn quhto strdnk.
Rdurbo1 Frinbo Mhdtobg Liy =392: 93; bdlpinhos
)-"%/&+'
(!*'
,.$3%9='
25*'?&6./;-&'
7/3/69&+'
85*'
1%+/9'
(:*'
Sirtnorsghps ine B`honts
Ehstrhmuthdn df Sirtnorsghp Uypos
Ibieolhb ]osoirbg
Hneustry
Mhdtobg
Dtgor=6/
93/
97/
56/
7
F]INBO1 MHDUOBG INE LOEUOBG IBUHVHUX
Rdurbo1 Frinbo Mhdtobg Liy =392: 9;6 bdlpinhos
Hneustry
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
14/35
Oxport tosthldny
go bdnehthdns tgit
rolihn untroitim`o
iro tgo ldst ehffhbu`t
td bdnquor, mut tgo ehvorshty
df hntuhthvo heois ine ip
prdibgos burront`y mohnkpursuoe stronktgons dur
bginbos td lijo hlpibtfu`
ievinbos. Is i liadr ibtdr
hn tgo rosoirbg bdllunhty,
Rindfh gis i strdnk hntorost
hn p`ibhnk hts eovo`dplont
toils hn in obdsystol df
`hvo`y rosoirbg. Eosphto dur
shzo, wo nooe pirtnors td
bdnfrdnt dur vhowpdhnts inetd go`p robi`hmrito dur pors
pobthvo ine rof`obthdns. Ht hs
fdr tghs roisdn tgit wo iro hn
bdnstint bdntibt whtg Mhdtobg
ine Loetobg bdlpinhos,
mdtg it tgo ontropronour ine
hnvostdr `ovo`. Ughs hs pirthbu
`ir`y truo hn Frinbo, wgoro gi`f
df dur rosoirbg toils iro `d
bitoe. Rindfh dffors hts hneus
trhi` jndw`oeko ine k`dmi`
lirjot ibboss hn pirtnorsghp
shtuithdns, ine hn roturn wo
robohvo in hlpdrtint bdlpdnont df broithvhty ine f`oxhmh`hty
frdl @hfo Rbhonbos stirtup
bdlpinhos.
Hn i pirtnorsghp, wgit hs ldst
hlpdrtint hs td brdss pitgs df
ton ine td wdrj tdkotgor ine
kot td jndw dno indtgor wo``
frdl tgo vory mokhnnhnk. Ud
roi``y muh`e sdlotghnk, ht hshlpdrtint td fhrst bdnfhrl tgit
tgo pirtnors sgiro tgo silo
uneorstinehnk df prdaobt
dmaobthvos ine thlo`hno, wghbg
i``dws tgo bd``imdritdrs td
offobthvo`y monbglirj tgohr
sbhonthfhb adurnoy tdkotgor.
Sgh`hppo Kdupht
Sgh`hppo KduphtVhbo Srosheont Bdrpdrito @hbonsos,
Rtritoky & Mushnoss Eovo`dplont
Rindfh
Eosphto dur shzo, wo nooe pirtnors td bdnfrdnt
dur vhowpdhnts
U9?
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
15/35
96
Sitonts
Sitonts Fh`oe
Sitonts Oxp`dhtoe
Frinbo$Ourdpo
_RI
]ost df [dr`e
9227
;88
95;;
93
9=
Sitonts Krintoe
67?
=65
55?
99
;5=
=25
=6;
Ugo hnto``obtui` prdporty ibthvhthos df Fronbg @hfo Rbhonbo bdlpinhos bdnthnuo td mo vory hntornithdni` hn nituro,is 53/ df oxp`dhtoe pitonts woro krintoe ohtgor my tgo _nhtoe Rtitos Sitont Dffhbo dr i ndnOurdpoin pitontdffhbo 'Fhkuro 9=(. Ovon ldro to``hnk hs tgo fibt tgit62/ df pitont ipp`hbithdns woro fh`oe whtg i ndnOurdpoinpitont dffhbo 'Fhkuro 93(.
Olp`dyhnk =5 podp`o ine givhnk moon hn mushnoss fdr i`ldst 93 yoirs, bdlpinhos oxp`dhthnk pitonts iro konori``ys`hkgt`y d`eor ine `irkor tgin tgo ivoriko fdr i`` survoy rospdneonts '== olp`dyoos ine 8 yoirs d`e(. Ughs yoirsrospdnsos rokirehnk pitont ibthvhty iro bdnshstont whtg ghstdrhbi` trones: Fronbg @hfo Rbhonbos bdlpinhos tonetd mrdieon tgohr hnto``obtui` prdporty kdi`s is tgoy eovo`dp ine dporito dvor i `dnkor porhde df thlo.
F]INBO1 MHDUOBG INE LOEUOBG IBUHVHUX
Rdurbo1 Frinbo Mhdtobg Liy =392: 923 bdlpinhos
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
16/35
Oxport tosthldny
uh`ehnk i rdmust not
wdrj df @hfo Rbhonbos
bdlpinhos hs i prhd
rhty fdr Frinbo. Ugo lobgi
nhsls df suppdrt fdr tgo sob
tdr iro hn p`ibo td eovo`dp tgo
pdtonthi` vi`uo df heois kono
ritoe my Fronbg rosoirbgorsine dur lhsshdn it mphfrinbo
hs td prdvheo i typo df `ovor
tgit wh`` offhbhont`y prdldto
tgo hneustrhi` bgilphdns df
tdldrrdw. Ehrobt ihe td hnnd
vithdn hs wgit hs nooeoe fhrst
df i``, tgrdukg sumshehos, bisg
ievinbos ine hntorostfroo
`dins. Ugon wo lust lihntihn
tgo prdkril df tix suppdrtstgit hs hn p`ibo, spobhfhbi``y
tgo ]osoirbg Uix Broeht 'BH](
ine tgo Xdunk Hnndvithvo
Ontorprhso 'AOH( eoshknithdn.
Fhni``y, wo nooe td md`stor
tgo oquhty hnvostlonts tgit
ibbdlpiny ontropronours
tgrdukg oibg stiko df tgohr
prdaobt. Ugo Mhdtobg ine
Loetobg toils it mphfrinbo
liniko i bdlp`oto pdrtfd`hd
df ehrobt ine hnehrobt fhnin
bhnk voghb`os tgit suppdrt
bdlpinhos it ovory stop df
tgohr eovo`dplont, frdl sooe
stiko td liturhty. Dur toils
ine oxports iro prosont i``
dvor tgo bduntry wdrjhnk td
kuheo ontropronours hn tgohroffdrts td put i strubturo
irdune tgohr hnndvithdns.
Dnbo wo givo lieo in hn
vostlont, i fhninbhi` ievhsdr
ine i sumaobt littor oxport
frdl mphfrinbo adhn tgo mdire
df ehrobtdrs df tgo bdlpiny
ine mokhn wdrjhnk td eovo`dp
`dnktorl vi`uo. Ovon hf tdeiy
mphfrinbo hs hnvostoe hn dn`y97 Sothtos ot Ldyonnos On
troprhsos, wo rolihn itton
thvo td tgo rhsj df eostimh`hzhnk
tgo prhvito hnvostdr lirjot.
@hjo dur poors hn tgo prhvito
sobtdr, wgd iro i`sd dfton dur
pirtnors, wo fivdr prdaobts
whtg strdnk hneustrhi` ro`o
vinbo ine prdfosshdni` li
nikolont toils.
Li`ys Forroro
Li`ys ForroroEhrobtdr df Hnvostlonts
Fdnes Rtritkhquo eHnvosthssolont
mphfrinbo
Dur oxports iro prosont i`` dvor tgo bduntrywdrjhnk td kuheo ontropronours
M9;
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
17/35
97
Ugoripouthb Srdeubts my Fdbus Iroi
Dnbd`dky
9;/
8/ 7/
5/ 5/ 5/
=8/
Hnfo
bthdus
ehsoisos
Bontri`
Norvd
us
Rystol
L
otimd`hsl
Bire
hdvi
sbu`ir
eovhb
os
Eorl
itd`dky
Sirishthb
eosoisos
6/
Dtgo
r
2/
Konothb
eosoisos
=/
Dptgi`l
d`dky
=/
]gul
itd`dky
=/
Hlluno
Rysto
l3
=3
93
23
/
FdbusIroi
=/
Hnf`illithdn
92
Rdurbo1 Frinbo Mhdtobg Liy =392: 8? bdlpinhos
Rdurbo1 Frinbo Mhdtobg Liy =392, eiti ndrli`hzoe td 933 bdlpinhos por yoir
Ugoripouthb Srdeubts my Rtiko df Eovo`dplont
78
?3
=3
53
63
73
933
3Srob`hnhbi` Sgiso 9 Sgiso = Sgiso 2 ]okhstrithdn Bdllorbhi`hzithdn
95
=337 =338 =393 =399 =39=
62
???;
=2=6
53=8
2529
=9=;
2?25
996 7 6 7 7 2 5 2 5
93;
9=
=3=6
Nulmor df Srdeubts
Rtiko dfEovo`dplont
Ugo phpo`hno df tgoripouthb @hfo Rbhonbos prdeubts uneor eovo`dplont rolihns rdmust hn Frinbo. Is hn yoirs pist,tgo edlhnint tgoripouthb iroi df fdbus rolihns Dnbd`dky '=8/(. Ughs yoir siw in hnbroiso hn prdeubts ieerosshnkHnfobthdus Ehsoisos '9;/ vs 7/ hn =399(, tgo Bontri` Norvdus Rystol '8/ vs ;/ hn =399( ine Lotimd`hsl'7/ vs 6/ hn =399(. Dn ivoriko, tgo 8? bdlpinhos eovo`dphnk tgoripouthb prdeubts iro 8 yoirs d`e, givo =?olp`dyoos, lihntihn 2 pirtnorsghps, spone 2.5L i yoir dn ]&E ine oxp`dht 95 pitonts.
=78 tdti` prdeubts woro eob`iroe tghs yoir, rinkhnk frdl tgo prddf df bdnbopt stiko td bdllorbhi`hzithdn, ine?9/ '8? df tgo 976( df bdlpinhos tgit rospdneoe td tgo survoy ropdrtoe givhnk i tgoripouthb prdeubt uneoreovo`dplont. Ugo oir`y, hnndvithvo stikos df prdeubt eovo`dplont rolihn eynilhb hn tghs yoirs bdgdrt, wgoro65/ df prdeubts woro ropdrtoe td mo hn tgo Srddf df Bdnbopt dr Srob`hnhbi` ]osoirbg stikos. =?/ df prdeubtsiro hn Sgiso H, HH dr HHH b`hnhbi` trhi`s ine, porgips ldst hlprosshvo`y, =? prdeubts iro it tgo bdllorbhi`hzithdnstiko, bdlpiroe whtg == hn =399.
F]INBO1 MHDUOBG INE LOEUOBG IBUHVHUX
Srdeubts
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
18/35
98
Ehikndsthb Srdeubts my Fdbus Iroi
Dnbd`dky
96/9?/
9=/
5/ 5/2/
98/
Hnfo
bthdus
ehsoisos
Bontri`N
orvd
us
Rystol
Lotimd`hsl
Ikrh,fd
de
]osoirbg
Rd`uthd
ns
Gdsphti`
Rd`uthd
ns
7/
Dtgo
r
2/ 2/ 2/ 2/
Ehkosthvo
eovhb
os
Hlluno
Rystol
]osphri
tdry
eovhb
os
Golitd`dky
=3
3
93
?
9?
FdbusIroi
/
9?
Dtgor Srdeubts;3 bdlpinhos ropdrtoe givhnk dtgor, ndntgoripouthb prdeubts uneor eovo`dplont, subg is hn vhtrd dr hn vhvdehikndsthbs, loehbi` eovhbos ine dtgor ievinboe tobgnd`dkhos. Dn ivoriko tgoso bdlpinhos iro 8 yoirs d`e,givo =9 olp`dyoos, lihntihn 2 pirtnorsghps, hnvost 9.?L hn ]&E innui``y ine oxp`dht 6 pitonts. I tdti` df78 Ehikndsthb prdeubts iro mohnk eovo`dpoe my 53 ehfforont @hfo Rbhonbos bdlpinhos. 98/ df tgoso Ehikndsthbs iro tirkothnk Dnbd`dky, wgh`o 96/ fdbus dn tgo Bontri` Norvdus Rystol ine 9?/ ieeross tgo HllunoRystol. Loehbi` Eovhbos bdlpinhos bdnthnuo td prdvheo in hlprosshvo stim`o df hnndvithvo prdeubts. Ughs
yoir siw 8 bdlpinhos ropdrt i tdti` df 98 loehbi` eovhbos uneor eovo`dplont, whtg ldst prdeubts fdbushnkdn Dnbd`dky '=6/(, Drtgdpoehbs '=9/( ine Birehdvisbu`ir '96/(.
Frinbo Mhdtobg
HSRON
Rindfh
] & E Hnvostlont " df Sgiso 9 " df Sgiso = " df Sgiso 2
=?= L
2=3 L
6,277 L
98 =5 6
9
?5
7
?5
?
=9
Bdlpirhnk tgo ]&E hnvostlonts lieo my twd Fronbg Sgirlibouthbi` bdlpinhos whtg tgdso df ?8 Mhdtobgnd`dky bdlpinhos frdl tgo Sindrili survoy eoldnstritos tgo offhbhonby df tgo @hfo Rbhonbos sobtdr hn Frinbo.[htg `oss ]osoirbg ine Eovo`dplont sponehnk, tgoso eynilhb @hfo Rbhonbos bdlpinhos hn Frinbo iro im`otd mrhnk ldro prdeubts hntd tgo b`hnhbi` trhi` pgiso tgin tgohr Sgirlibouthbi` hneustry poors. Ugo ehspirhthossoon hn tghs bgirt go`p oxp`ihn tgo strdnk robont krdwtg hn tgo nulmor df now`y ipprdvoe loehbithdns tgitdrhkhnito frdl tgo edlihn df mhdtobgnd`dky.
Bdlpirhsdn whtg Fronbg Sgirlibouthbi` Bdlpinhos
Rdurbo1 Frinbo Mhdtobg Liy =392: 53 bdlpinhos
Rdurbo1 Frinbo Mhdtobg Liy =392: ?8 bdlpinhos: MhdBontury
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
19/35
=3
K`dmi` Sorspobthvo df Robtdr Funehnk
Ovd`uthdn df @hfo Rbhonbos Hneustry Funehnk 'L(
939 9=9927
=32
9=
968
=337 =338 =393 =399 =39=
Vonturo Biphti`
HSD
933
=33
233
533
?33
3
Robdneiry Sum`hb Dfforhnks
972
972
936
8=
;5
956
73
937
=392 XUE
2?29
L
Xoir
96
Ugo tdti` hnvostlont lieo hn tgo Fronbg @hfo Rbhonbos sobtdr hn =39= rdso my =;/ td 265 L. Krdwtg wiserhvon my strdnk eoline frdl tgo pum`hb lirjots '*?8/(, is tgo hneustry ropdrtoe ohkgt subbossfu` HSDs. VonturoBiphti` funehnk '*95/( ine Robdneiry Sum`hb Dfforhnks '*7/( siw onbdurikhnk yoirdnyoir hnbroisos is wo``.
Rdurbo1 Frinbo Mhdtobg Liy =392
Hn robont yoirs, fhninbhi` suppdrt fdr tgo @hfo Rbhonbos sobtdr hn Frinbo gis drhkhnitoe prhlirh`y frdl
pum`hb sdurbos, mo tgoy pum`hb stdbj lirjots dr kdvornlont prdkrils. HSD ibthvhty my @hfo Rbhonbosbdlpinhos roibgoe hts ghkgost `ovo` ovor hn =39=, whtg robdres mohnk mrdjon mdtg hn torls df tgo nulmordf HSDs bdlp`otoe ine tgo tdti` ildunt rihsoe. Ontropronours i`sd bdnthnuo td eopone goivh`y dn tgoliny kdvornlont prdkrils tgit suppdrt ydunk, hnndvithvo bdlpinhos whtg ibthvhthos fdbusoe dn]osoirbg ine Eovo`dplont hn ievinboe sbhonthfhb fho`es.
F]INBO1 FHNINBHNK HNNDVIUHDN
=39= =392 Bginko
HSD
VB
RSD
993 29 ;=/
5?
=;
937
2?
953/
23/Udti` 97= 9;5 5/
Funehnk Bdlpirhsdn1 Ainuiry td Liy 'L(
Rdurbo1 Frinbo Mhdtobg Liy =392
Xoir
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
20/35
=9
_so df Sum`hb Lirjots
58
9= 32;
=33? =336 =33; =337 =338
Ildunt ]ihsoe " df HSDs
53
73
9=3
963
3
92?936
=393
8=
=399
956
=39=
29
=
5
6
7
93
3 Xoir
Nulmordf HSDs
Ildunt]ihsoe 'L(
=
2
?
9
;
6
7
2
I tdti` df956 L wis rihsoe frdl tgo pum`hb lirjots hn =39=, i strdnk hnbroiso mdtg hn vi`uo '*?8/( ine
hn nulmor '*22/( bdlpiroe whtg =399. Ugo `irkost dporithdns woro bdlp`otoe my EMV Uobgnd`dkhos'59 L(, ODR Hlikhnk '27 L( ine Iedbhi '=; L(. Is hn =399, tgoro wis i proedlhninbo df LoeUobgbdlpinhos ildnk tgdso fh`hnk fdr HSDs hn =39= '6 df 7 hn =39= vs. ? df 6 hn =399(. Ugo ro`hinbo dn pum`hbhnvostdrs bdnthnuos td mo i joy rosdurbo fdr tgo @hfo Rbhonbos sobtdr, is tgroo bdlpinhos givo i`roiey bdneubtoe HSDs hn =392, rihshnk i bdlmhnoe 29 L.
=392 XUE
Ovd`uthdn df Fronbg @hfo Rbhonbos HSDs dn NXRO Ourdnoxt 9;
Rdurbo1 Frinbo Mhdtobg Liy =392
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
21/35
Oxport tosthldny
gh`o tgo pd`hbhos
df goi`tg biro
rohlmursolont
rolihn tgo prordkithvo df
oibg lolmor stito, tgo Ou
rdpoin @hfo Rbhonbos sobtdr
gis mobdlo i roi`hty hn austton yoirs. Ontropronourhi`
toils iro ldro oxporhonboe
ine hntornithdni` tdeiy ine
tgoy dfton bdlmhno i lhx df
sbhonthfhb ti`ont frdl liny ehf
foront bduntrhos. It tgo silo
thlo, hnvostdr krdups nd `dn
kor fdbus tgohr hnvostlonts
oxb`ushvo`y dn dno bduntry
ine givhnk i dbi` hnvostdr ittgo tim`o gis mobdlo `oss df
i nobosshty. Ughs Ourdpoin
bdnvorkonbo hs soon hn pum`hb
fhsbi` pd`hby is wo``, whtg
oxilp`os `hjo tgo ]osoirbg
Uix Broeht pissoe my tgo
Fronbg kdvornlont hnsphrhnk
dtgors hn Ourdpo td onibt sh
lh`ir loisuros, ndtim`y tgo
_nhtoe Jhnkedl ine Kor
liny. Ugo sgirhnk df bdlpo
tonbhos ildnk Ourdpoin ro
ku`itdry ikonbhos gis fhni``y
subbooeoe hn prdvhehnk i
trinsnithdni` porspobthvo ine
wo iro mokhnnhnk td soo i Ourdpoin spobhi`ty hn bortihn ed
lihns df rosoirbg, subg is
Loehbi` Eovhbos.
Ugo hneustry hs Ourdpoin mut
sd hs tgo brhshs ) Xdu givo td
fhkgt td soo ydur prdaobt krdw,
ine tgit hs truo ovorywgoro
hn Ourdpo. Ndnotgo`oss, tgo
sobrot fdr subboss hs truo ovorywgoro1 ontropronours nooe
td mo ilmhthdus ine bdnfheont
ine tgoy nooe td fhne hnvos
tdrs tgit sgiro tgohr vhshdn. Ui
jhnk tgo thlo td eobheo gdw
td broito ine sgiro tgo vi`uo
df in heoi hs vhti``y hlpdrtint.
]ifi`o Udrealin
]ifi`o Udrealin, LELinikhnk Sirtnor
Rdfhnndvi Sirtnors
Ugo sgirhnk df bdlpotonbhos ildnk Ourdpoin
roku`itdry ikonbhos gis fhni``y subbooeoe
[==
F]INBO1 FHNINBHNK HNNDVIUHDN
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
22/35
Dtgor fdrls df fhninbhnkRooe fhninbhnk rolihns i brubhi` bdlpdnont td tgo oir`y stikos df tgo mushnoss eovo`dplont byb`o hn tgo@hfo Rbhonbos sobtdr. Rooe funehnk my Fronbg Mushnoss Inko`s wis stim`o hn =39= hn bdlpirhsdn whtg =399,ildunthnk td aust dvor? L eurhnk mdtg yoirs.
I`sd hn =39=, Fronbg @hfo Rbhonbos bdlpinhos woro ildnk tgo oir`y iedptors df brdwefunehnk, i now, hntor
notbdllunhtymisoe funerihshnk bdnbopt tgit gis mobdlo dno df tgo gdttost trones fdr fhninbhnk hnndvithdnirdune tgo wdr`e. Hn Dbtdmor, Udu`dusomisoe mhdtobg bdlpinyINUIMHD robdreoe wgit gis moon eosbrhmoeis tgo fhrst brdwefunehnk dporithdn ovor bdlp`otoe my i mhdtobg bdlpiny.
Vonturo Biphti`
Ehstrhmuthdn df VB Funehnk 'L(
57
992
6;
=393 =399 =39=
53
73
9=3
963
=33
3
73
?=
?3
6
6
Mhdtobg
B`ointobg
Loetobg
" df eoi`s
=?
Ildunt ]ihsoe 'L(
Xoir
27
59
93
=3
23
53
?3
Nulmor df Dporithdns
3
97
Hnvostlonts my vonturo biphti` funes hnbroisoe hn =39= td 927 L, ikihnst9=9 L hn =399. I tdti` df 59eoi`s woro dmsorvoe, bdlpiroe whtg 27 hn =399, wgh`o tgo ivoriko ildunt hnvostoe por eoi` krow frdl2,= L hn =399 td 2,? L hn =39=. I``dbithdn df hnvostlonts my funehnk rdune wis wo`` ehstrhmutoe, whtgRorhos M fhninbhnks oiehnk tgo wiy it58 L, fd``dwoe my Rorhos B fhninbhnks df25 L, Rorhos I fhninbhnksdf=6 L ine Rorhos E fhninbhnks df93 L. Ughs ehstrhmuthdn bdlpiros fivdrim`y whtg =399, wgon dvor?5/ df VB ourds woro i``dttoe eurhnk Rorhos B rdunes.
Hnvostlonts hn Mhdtobgnd`dky bdlpinhos `oe tgo oxpinshdn hn funehnk '*67/( ine go`poe bdlponsito fdri erdp hn Loetobg eoi`s '=2/(. Uwd `irko rdunes hn =39= hnb`ueoe i 92 L Rorhos M fhninbhnk my Sdxo``R.I. ine i 9=,5 L Rorhos B fhninbhnk my UxBo`` R.I. I vory strdnk stirt td =392 gis moon uneorwiy is wo``,whtg i 2= L Rorhos I fhninbhnk my KonRhkgt Mhd`dkhbs ine i =7 L Rorhos E fhninbhnk my Ruporsdnhb Hlikhno mdtg mohnk inndunboe hn Iprh`.
Bdrpdrito VonturoBdrpdrito Vonturo hnvostlonts lieo my Sgirlibouthbi` bdlpinhos p`iy in hlpdrtint rd`o hn suppdrthnk tghshnndvithvo sobtdr. Lrhoux Eovo`dplont bdnthnuoe td suppdrt tgo eovo`dplont df @ydnmisoe loetobg bdlpiny Mhdlup ine Rtrismdurkmisoe ehikndsthbs fhrl MhdFh`l Bdntrd`, wgh`o Ndvirths Vonturo tddj pirt hn
tgo Rorhos I rdune df dpgtgi`lhb tgoripouthbs bdlpiny Konshkgt Mhd`dkhbs ine Mdogrhnkor Hnko`gohlVonturo Fune robont`y inndunboe p`ins td hnvost hn dbu`ir tgoripouthbs fhrl Oyovonsys.
Rdurbo1 Frinbo Mhdtobg Liy =392
=2
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
23/35
=5
BH]
Ugo rosoirbg tix broeht 'BH]( hs i tix roeubthdn eoshknoe td onbduriko tgo ]&E ibthvhthos df Fronbg bdlpinhos.79 bdlpinhos hn tghs yoirs stuey ropdrtoe tijhnk ievintiko df tgo rosoirbg tix broeht fdr i tdti` monofht dfi`ldst67 L. ?=/ df bdlpinhos eriwhnk dn tgo rosoirbg tix broeht givo 9 td 93 olp`dyoos ine 67/ givomoon hn dporithdn fdr oss tgin 93 yoirs, sgdwhnk tgit tghs hlpdrtint prdkril bdnthnuos td monofht sli``, ydunkine hnndvithvo bdlpinhos. Ugoso 79 bdlpinhos robohvhnk tgo rosoirbg tix broeht tdkotgor ibbdunt fdr 98 prdeubtshn Sgiso HH b`hnhbi` trhi`s, 6 prdeubts hn Sgiso HHH b`hnhbi` trhi`s ine 96 prdeubts ontorhnk bdllorbhi`hzithdn.
9=
9;
=336 =33; =337 =338 =393
5
7
96
=3
3
=399
" df now bdlpinhoseob`irhnk AOH stitus
Xoir
=39=
9=99 99
8
=
Rdurbo1 Frinbo Mhdtobg Liy =392
F]INBO1 FHNINBHNK HNNDVIUHDN
98
Kdvornlont Ruppdrt
Krints ine ]osoirbg RumshehosIldnk tgo 976 rospdneonts td tghs yoirs survoy, 927 ropdrtoe robohvhnk i krint dr sumshey td suppdrt tgohribthvhty hn =39=. Ughs fhninbhi` isshstinbo wis ehstrhmutoe is fd``dws1
`?= bdlpinhos robohvoe in hnvostlont sumshey:
`65 bdlpinhos robohvoe dporithnk sumshehos, tdti`hnk 53,? L:
` 75 bdlpinhos robohvoe i ropiyim`o `din, tdti`hnk ;2 L:
` 28 bdlpinhos robohvoe suppdrt frdl DROD, tdti hnk 69 L:
` =2 bdlpinhos robohvoe suppdrt frdl tgo Ikonbo Nithdni`o eo ]obgorbgo 'IN](, tdti`hnk ?.? L:
` =2 bdlpinhos robohvoe suppdrt frdl i Ourdpoin prdkril, tdti`hnk 7,2 L.
Xdunk Hnndvithvo Ontorprhso Rtitus 'AOH(
AOHUgo Xdunk Hnndvithvo Bdlpiny 'AOH( stitus, eovo`dpoe my tgo Rtritokhb Bdunbh` fdr Hnndvithdn ine suppdrtoemy Frinbo Mhdtobg hn =335, prdvheos i nulmor df tix ine sdbhi` soburhty oxolpthdns fdr SLOs tgit i``dbito it`oist9?/ df tgohr tdti` bdsts td rosoirbg ine eovo`dplont. 963 bdlpinhos olp`dyhnk 873 tdti` wdrjors hn tgo
]osoirbg ine Eovo`dplont hn Mhdtobgnd`dky sobtdr monofhtoe frdl tgo AOH stitus hn =393, ibbdrehnk td tgo=39= EKBHR ropdrt vi`uithdn eu ehspdshthf AOH. ?3/ df bdlpinhos hn tghs yoirs stuey ropdrtoe givhnk dptoefdr tgo AOH stitus. Furtgorldro, i`` 92 df tgo bdlpinhos hn tghs yoirs bdgdrt tgit woro broitoe hn =399 dr =39=eob`iroe givhnk ipp`hoe fdr tgo stitus. Ugo AOH stitus rolihns i brubhi` suppdrt fdr ontropronours hn tgo @hfoRbhonbos sobtdr.
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
24/35
Oxport tosthldny
neustrhos df tgo futuro
`hjo Mhdtobgnd`dky ine
Loehbi` ]osoirbg, is
wo`` is ]onowim`o Onorky
ine GhkgUobg, wh`` mo tgo
prhdrhty df mphfrinbo, wgh`o Lh
brdontorprhsos 'USO(, Rli``
ine Loehul Ontorprhsos'SLO( ine Hntorloehito Rhzo
Ontorprhsos 'OUH( wh`` mo tgo
tirkot strubturo df tgo bdl
pinhos tgit wo wh`` sooj td
suppdrt. @hfo Rbhonbos hs dno
df tgroo liadr stritokhb sob
tdrs df fdbus tgit gis ghstdrh
bi``y soon strdnk suppdrt
frdl tgo drkinhzithdns tgit
lijo up mphfrinbo. Ugo hntokrithdn df FRH, DROD ine BEB
Ontorprhsos i``dws mphfrinbo
td dffor bdlpinhos i wheo eh
vorshty df fhninbhi` suppdrt dp
thdns ine khvos us tgo bipi
mh`hty td hntorvono dn mdtg tgo
bisg ine oquhty pdshthdns df
bdlpinhos td suppdrt tgohr
eovo`dplont.
Ugo strubturo df tgo fhninbhnk
bgihn hs i bdnstint bdnborn
df tgo Fune df Funes toil.mphfrinbo wh`` bdntrhmuto td
tgo iunbg df now hnvostlont
toils, prdvheoe tgoy iro ox
porhonboe, broehm`o ine iro
fdbusoe dn sumaobts tgit iro
hnieoquito`y dr ndt it i`` bd
voroe my tgo burront lirjot.
Hneooe wo iro p`innhnk td
pirthbhpito hn funerihshnks fdr
sovori` now @hfo Rbhonbosfunes tghs yoir, is tgroo eds
shors iro uneor b`dso oxilh
nithdn it tgo ldlont.
Siu`Frindhs Fdurnhor
Siu`Frindhs FdurnhorOVS Hnndvithdn Ehvhshdn
mphfrinbo
@hfo Rbhonbos hs dno df tgroo liadr stritokhb
sobtdrs df fdbus
H=?
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
25/35
=6
Mrizh`
Biniei
_RI
Korliny
Hti`yRpihn
Rwoeon
_nhtoeJhnkedl
Fhn`ine
Sd`ine
Sdrtuki`
Rwhtzor`ine
Notgor`ines
Mo`khul
Frinbo Iustrhi
Eonlirj
]dlinhi
9 =
=7 27
9
9 = 2
9
6 8
9 8
9
9
=
9 5
=
= 6
9 ?
2 2
? 95
HNUO]NIUHDNI@ SO]RSOBUHVOR
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
26/35
=;
Iustri`hi
BghniAipin
Rhnkipdro
Uiwin
Hsrio`
Now Qoi`ine
Frinbo
2
? =Rdutg Jdroi
9
= ;
9 9
=
9
9
Nulmor dfFronbg bdlpinhos
hlp`intoe
Nulmor dfpirtnorsghps my
Fronbg bdlpinhos
Rdurbo1 Frinbo Mhdtobg Liy =392
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
27/35
=7
@hfo Rbhonbos Bdlpinhos dn tgo NXRO Ourdnoxt$I`tornoxt
==
929
=33; =337 =338 =393 =399
Mo`khulFrinbo
?3
933
9?3
=33
=?3
3
233
Notgor`ines
87 936 8=
=39=
92?
?6
9=
956
Xoir
=3
@hfo Rbhonbos HSDs hn OurdpoHn robont yoirs Frinbo gis eriwn dn tgo rosdurbos df tgo pum`hb lirjots ldro ibthvo`y tgin dtgor @hfo Rbhonbossobtdrs hn Ourdpo. Frdl =33; tgrdukg =39=, tgoro woro =; subbossfu` HSDs dn tgo NXRO Ourdnoxt dr I`tornoxtoxbginko bdneubtoe my Fronbg @hfo Rbhonbos bdlpinhos tgit rihsoe i tdti` df589 L. Dvor tgo silo thloporhde, tgoro woro shx HSDs my Mrhthsg @hfo Rbhonbos bdlpinhos dn tgo @dnedn Rtdbj Oxbginko tgit rihsoe i tdti`df27 L, tgroo HSDs my Rwhss @hfo Rbhonbos bdlpinhos dn tgo RHW Rwhss oxbginko tgit rihsoe BGF 92; L inetwd HSDs my Korlin @hfo Rbhonbos bdlpinhos dn tgo Eoutsbgo Mrso tgit rihsoe 57 L.
2 9?=L
? 9;8L
2;L
Frinbo
Mo`khul
Notgor`ines
Lirjot Biphti`hzithdns my Bduntry1 NXRO Ourdnoxt ine I`tornoxtMhdtobgnd`dky ine Loehbi` Oquhplont Bdlpinhos 'L(
=6 df tgo 2; Ourdpoin bdlpinhos trieoe dn tgo NXRO Ourdnoxt ine I`tornoxt oxbginkos whtg tgo hneustryb`isshfhbithdn df Mhdtobgnd`dky dr Loehbi` Oquhplont iro df Fronbg nithdni`hty, wgh`o Fronbg bdlpinhos bdnsthtuto6=/ df tgoso bdlpinhos tdti` lirjot biphti`hzithdn.
@hfo Rbhonbos HSD Funerihshnk my Bduntry1
NXRO Ourdnoxt ine I`tornoxt
'9(
'=(
'?(
'9(
'9(
'9( ';('6(
'7(
Rdurbo1 Frinbo Mhdtobg Liy =392:
'n( < nulmor df HSDs
Ildunt]ihsoe 'L(
Rdurbo1 Mdursdrili, 9? Liy =392
HNUO]NIUHDNI@ SO]RSOBUHVOR
=9
2?3
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
28/35
NXRO NOWU Mhdtobg Hneox
=8
Ibbdrehnk td i Ainuiry =2, =392 NXRO Ourdnoxt pross ro`oiso, tgo mhdtobgnd`dky sobtdr wis dno df tgo tdpporfdrlhnk sobtdrs hn =39= whtg tgo SinOurdpoin Noxt Mhdtobg Hneox kihnhnk6;.58/. It tgo sukkosthdn dfFrinbo Mhdtobg, tgo Noxt Mhdtobg Hneox wis broitoe hn =337 td go`p eriw ittonthdn td tghs hnndvithvo sobtdrhn Ourdpo. Ugo Noxt Mhdtobg Hneox hs bdlpdsoe df bdlpinhos `hstoe dn ohtgor tgo Ourdnoxt dr I`tornoxtlirjots tgit givo in HBM b`isshfhbithdn df 5?;2 'Mhdtobgnd`dky(: 96 df tgo =2 bdlpinhos tgit bdnsthtutotghs hneox iro Fronbg.
NOWU Mhdtobg Hneox
;6=,29
23 ebolmro
=399
29 ebolmro
=39=
9 =;6,79
Rdurbo1 NXRO Ourdnoxt Liy =392:
==
Fdbus dn Fronbg pum`hb`y qudtoe bdlpinhos hn @hfo Rbhonbos
Hn =39=, tgoro woro 26 Fronbg @hfo Rbhonbos bdlpinhos `hstoe dn pum`hb stdbj oxbginkos. Ldst iro `hstoe hn Sirhs dn ohtgor tgo NXRO Ourdnoxt dr I`tornoxt oxbginkos,wgh`o dno bdlpiny, F`ilo` Uobgnd`dkhos, hs `hstoe dn tgo _R NIREIY. Hn =39=, tgoso26 pum`hb`y`hstoe bdlpinhos bdlmhnoe td olp`dy 2 662 olp`dyoos, hnvost23= Lhn ]&E ine konorito ?72 L hn rovonuos '*8/ frdl =399(. Ugo bd``obthvo lirjotbiphti`hzithdn df tgoso bdlpinhos dn Liy 9?, =392 wis noir`y 5,9 M.
Voxhl, i LoeUobg bdlpiny misoe noir Udu`duso wdrjhnk dn troitlonts fdr triulithbsphni` pitgd`dkhos, wdn tgo =39= NXRO I`tornoxt Srhzo fdr tgo subboss df hts HSD hn Iprh`ine fdr tgo strdnk porfdrlinbo df tgo stdbj tgit onsuoe.Birlit, in H`oeoFrinbo iroibdlpiny tgit robont`y kihnoe ipprdvi` td bdneubt gulin b`hnhbi` trhi`s df hts irthfhbhi`goirt, bdnthnuos td gd`e tgo ghkgost lirjot biphti`hzithdn 'dvor?=? L dn Liy =9,=392( ildnk tgo ldro tgin =33 tdti` bdlpinhos `hstoe dn tgo NXRO I`tornoxt stdbjoxbginko. Mdtg df tgoso bdlpinhos woro fhninboe my Uruff`o Biphti`, wghbg wis tgoldst ibthvo vonturo fune suppdrthnk Fronbg SLOs hn =39= ibbdrehnk td tgo -HnehbitourBgiussdn Fhninbo.-
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
29/35
Oxport tosthldny
htg dvor 23 pum`h
b`y qudtoe @hfo
Rbhonbos bdlpi
nhos, ht hs b`oir tgit i `okhthlito
notwdrj df lituro Mhdtobg ine
Loetobg bdlpinhos oxhsts td
eiy hn Frinbo. Ugo sobtdr gisprdkrossoe riphe`y hn Frinbo
dvor tgo ist 5 dr ? yoirs, wgh`o
krdwtg hn ldst dtgor Ourdpoin
bduntrhos gis ovo`oe dff. Rup
pdrt frdl fhsbi` pd`hby 'BH]( gis
moon i strdnk erhvor, mut sd
gis tgo ghkg qui`hty df sbhonth
fhb oeubithdn hn tghs bduntry.
K`dmi``y spoijhnk, Frinbo hs
gd`ehnk pibo hn tgo hnndvithdnribo ine lihntihns i roi` pd
tonthi` fdr eovo`dphnk ehsrup
thvo tobgnd`dkhos hn i virhoty
df fho`es, subg is loehbi` hli
kory, sphni` tgoripouthbs ine
hllundtgoripy.
Ugo bdntrist whtg tgo _nhtoe
Rtitos rolihns shknhfhbint hn
rokire td dno ossonthi` pdhnt1
brhthbi` liss. Sum`hb`y trieoe
Fronbg @hfo Rbhonbos bdlpi
nhos typhbi``y olp`dy 9? td 23
ldst`y ]&E wdrjors ine iro
fdbusoe prhlirh`y dn tgo eovo
`dplont df dno f`iksghp prd
eubt td mo prdldtoe my wiy df
i pirtnorsghp whtg i `irkor hn
eustrhi` bdlpiny. Ughs ldeo`
gis lieo ht sdlowgit unroi`hsthb fdr i bdlpiny td rolihn
hneoponeont wgh`o krdwhnk td
tgo shzo df in hneustry `oieor
ine tgo unfivdrim`o obdndlhb
ine roku`itdry onvhrdnlonts
givo bdlpduneoe tgo bgi`
`onko. Ud ittihn brhthbi` liss,
i stritoky df oxtorni` krdwtg
nooes td tijo dvor ine ibbo
`orito tgo eovo`dplont df durldst prdlhshnk prdaobts. Hn pi
ri``o` whtg tghs, ti`ontoe hnehvh
eui`s whtg bdllorbhi` ine
fhninbhi` mibjkrdunes nooe td
mo roiey td ibbdlpiny tgoso
futuro hneustry oieors is tgoy
krdw ine lituro. Hneooe, tgo
ovonts df =39= hn Frinbo ine
Ourdpo sgdwoe tgit i now
ipprdibg `hjo tghs bin mo sub
bossfu`.
Berhb Ldroiu
Berhb Ldroiu
Ehrobtdr , Goi`tgbiro
Mryin Kirnhor & Bd
K`dmi``y spoijhnk, Frinbo hs gd`ehnk pibo hn tgo
hnndvithdn ribo
[23
HNUO]NIUHDNI@ SO]RSOBUHVOR
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
30/35
29
Rdurbo1 Edw Adnos Vonturo Rdurbo
Bdlpirhsdn df VB Fhninbhnk hn Ourdpoin @hfo Rbhonbos1 =337=39=
7 56
?3
33
?3
33
?3
3Iustrhi Mo`khul Eonlirj Frinbo
=2
=337
69
2=
ldunt df Funehnk 'L(
Bduntry
33
?3
Korliny Notgor`ines Rpihn Rwoeon Rwhtzor ine _nhtoeJhnkedl
6
?
Loehbi` Eovhbosine Oquhplont
?=
?=
=8??
7=9
?
=8??
9
5
67
79
7
59
;933
23
7==
638=
52
=9
?2
;6
=9
93=
8? 92;
7=
56
;2
75
=9
55
=3;
?;
=6?
989
=
26
933
?9
;;
869
=9
8
9 59=2 2?92
23
= 8?
92 27
;=5?
?5
97
5
=?
93
6
=8
??
56
?5
25
92325
87
65
=38
9?9
7?
95=
?=
62
222
99?
958 95?
96?
=79
33
?3
Mhdpgirlibouthbi`s=338 Loehbi` Eovhbos
ine Oquhplont
Mhdpgirlibouthbi`s=393 Loehbi` Eovhbos
ine Oquhplont
Mhdpgirlibouthbi`s
=399Loehbi` Eovhbosine Oquhplont
Mhdpgirlibouthbi`s=39=
Loehbi` Eovhbosine Oquhplont
Mhdpgirlibouthbi`s
Ibbdrehnk td tgo Edw Adnos Vonturo Rdurbo eitimiso, oquhty hnvostlonts hn VBmibjoe Ourdpoin @hfo Rbhonbosbdlpinhos erdppoe my =7/ hn =39=, frdl 9.2M hnvostoe vhi =55 eoi`s hn =399 td 8?3L hnvostoe vhi9;? eoi`s hn =39=. Ughs erdp wis erhvon my i ?3/ yoirdnyoir eob`hno hn Ourds hnvostoe hn Loehbi` Eovhbosine Oquhplont bdlpinhos. Hnvostlonts lieo hn Robdne ]dune ine @itor ]dune fhninbhnks hn Ourdpo wororo`ithvo`y stim`o, wgh`o tdti` Ourds i``dbitoe td Fhrst ]dune fhninbhnks hn =39= erdppoe ==/ bdlpiroe td=399 `ovo`s.
Oquhty fhninbhnk df vonturofuneoe bdlpinhos virhos eristhbi``y frdl yoir td yoir hn liny bduntrhos hn Ourdpo.I`tgdukg `ovo`s df fhninbhnk hn Frinbo hn =399 ine =39= woro mo`dw tgo ?yoir ivoriko, vonturo biphti`hnvosthnk hn Frinbo bdlpiros fivdrim`y whtg Ourdpoin poor bduntrhos.
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
31/35
2=
IM RBHONBO
]ovonuo =39='J(
@hst df pum`hb bdlpinhos hn =39=
9 253
]ovonuo =399'J(
]&E =39='J( Olp`dyoos
Lirjot Bip 'Ldn 9?$?$=392(
" dfSrdeubts
9 935 7 ;=? 68 ?;=,2 5
BDLSINX
IEDBHI ; 2=6 2 ;77 99 ;75 ;9 62,7 5MHDI@@HINBO SGI]LI 5 355 2 =29 8 233 ?? ;;,? 8
MHDRXNOW 6 356 9 986 2=; =? ;,= 2BI]LIU 6 939 == 532 2; ?=7,= 9
BO@@OBUHR =9 32= 9? 882 97 879 ==7 996,2 6EMV UOBGND@DKHOR = ;;; 9 7;2 99 ?;8 2; 995,? 2
EOHNDVO 667 62; 2 25? 2= ?=,8 2
EHIKNDRUHB LOEHBI@ =8 562 == ;2; 756 7= 9;,9 8ODR HLIKHNK 93 285 ; ?89 = 965 ?2 76 =
F@ILO@ 98 8=5 =5 77? 98 82? =?3 85 6KONFHU 6 393 6 ;;7 99 295 ;6 99;,2 =
KOND[IX 7 758 7 77; 2 5;5 n$i 7,5K@DMI@ MHDONO]KHOR 9 ;85 =75 = 8;7 27 ?9,9
GXM]HKONHBR 5 8=; 6 ?8? = 2;? 5; 96,9 2HNNIUO SGI]LI 95 =7= 99 ;53 92 59; 79 87,2 7
HNUOK]IKON 5 736 5 728 9 299 =6 9;,? 9HNU]IRONRO ? 962 2 ?27 9 =33 58 98,; 9
HSRDKON$YHIKON LI]ROH@@O 92 766 93 936 2 6=2 ;5 ;3,2LI_NI JOI UOBGND@DKHOR 93 =7= ? 8;6 2 =6= ;? 92?,6 9
LOEHIN UOBGND@DKHOR 9 3=8;5=
= 789 5? 5;,= 9
LOUIMD@HB OWS@D]O] = 689 9 587 7 39; 93= 6=,=NINDMHDUHW 8;3 9 263 5 29= 29 69,8 2NODVIBR 995 28= ? 538 =2 26,5 2
NHBDW 7 26? 766 6 5;9 27 989,8 6NDVIBXU 9 93= ?38 8 =9,6 9
RUI@@O]KONOR =?5 ;;2 =?9 926 27 633 9 933 68;,; 5
RUONUXR = ?29 9 52= = 792 2? 937,= =UGO]IEHIK 7 ;89 93 87; 9 =33 58 96,7 ?U]INRKONO 92 369 95 556 57 6;8 =;? =72,? 6
VOWHL = =78 = 5== 9 959 53 5;,5 =VHVI@HR ? 838 9= ??? 9= 77? 99= 9==,? =
VHRHDLOE K]D_S 92 735 9= ?66 7= 7,2Rdurbo1 Frinbo Mhdtobg Liy =392: MhdBontury
` MHDI@@HINBO SGI]LI1 @drilyb, Rhtivhk` MHDLOEHBI@ UHRR_OR1 Bo``wom` BO@@OBUHR1 BinBo``, bKSR jht, EorliVix, gORBLB, ghSRGOS,UI@ONR` BD@BDL1 Eonerhehik, EonerhKrift Sd`y@yshno 'EK@(` EMV UOBGND@DKHOR1 Vhisjhn, Ehi``ortost` EHIWGDNGHU1 Ib`irusEx, UYR'Uotinus Yuhbj Rthbj(` EDRHRDFU1 OSHkriy, HRDkriy, L_=not, S@INOU DNBD` O'XO( M]IHN1 Ldmh`o OMU, LoyoINI@XRHR, LoyoSI]IEHKL S@IXO]` F@ILO@ UOBGND@DKHOR1 Loeusi, @hquhUhlo, Lhbrdpulp, Urhkkor @dbj,Eo`hVix` F@_HKONU1 LFBR, ORR`F@_DSUHBR1 F`udmoil, Inkhdstilp, RonthEyo, Inkhd`dno, F`udsthbj` KONDLHB VHRHDN1 FRGEBdlmhnk tost` K]IFUXR1 KriftysYuhbjRot, KriftysGMR ine KriftysMBS` GOLI]HNI1 Goldxbo``
` HLIWHD1 Rphrd`opt, Urd`dvd`` HN BO@@ I]U1 HBIFobthn, HBINthmdehos` HNNDSRXR1 HnndRbin` HNUOK]IKON1 I]HRJ` JDO@HR1 _rdstithdn` LI_NI JOI UOBGND@DKHOR1 Bo``vhshd, KistrdF`ox, Bgd`inkhdF`ox,Bgd`inkhdsbdpy, Bd`dF`ox, I`vodF`ox, IYF`ox98` LOEHIN UOBGND@DKHOR1 @LR@oshdn Linikolont Rd`uthdns` NDVIBXU1 NdviSropSrdbossdr Rystol` N_U]HI@XR LOEHBI@ N_U]HUHDN1 Bistiso, Sd`yed`` DU]21 BIBHS@HY=3, BIBHBD@=3UGO]IEHIK1 FHEHR, @HRI UribjorU]DSGDR1 S`ito ]_NNO] GE` VOWHL1 RphnoAibj` VHVI@HR1 OM66 Bo`` @hno, VHVIHRbroon
EHIWDNGHU ? 533 ? 333 6 872 938 59,8 ;
LOEHB]OI HNUO]NIUHDNI@ =3 ;33 9 2=6 27 65,? ==98 3??
Y_INUO@ ?3 58= ? ;33 9;= 8,8 =7?9 366
9; 878
9 589
895
INNOW
BDLLO]BHI@HQOE S]DE_BUR
;;
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
32/35
IIMILIMBO@@MHDIENHEIEDBHIIEVINBOE MHDEORHKNIFFHBGOLIFFH@DKHBIK_OUUINU MHDUOBGI@IWHII@KONHBRI@HQO SGI]LI H OU HH
I@QS]DUOBU RIRILI]DJ MHDUOBGND@DKHORINIBDNEI SGI]LIINIKONORHR MHDUOBGND@DKHORINHLIRBDSOINR MHDUOBGINUIKONOISUXR SGI]LIBO_UHBI@RI]BGHLLOE RI]@IU@INK]ILIU@INUHB MDNO RB]OONIWONHRIWD RBHONBO
I
M BO@@ EORHKNMHDI@@HINBO SGI]LIMHDI@UO]NIUHVORMHDBXUOWMHDKI@ONXRMHDKOLLIMHDLOEHBI@ UHRR_ORMHDL+_SMHDSGXUHRMHDRONUOBMHDU]HI@MHDVH]DN
M
E
O'XO(M]IHNOFFHL_NOONUO]DLOO]XUOBG SGI]LIO_JI]XR
O
FO]LONUI@KF@ILO@ UOBGND@DKHORF@D[KONOF@_HKONUF@_DFI]LIF@_DSUHBRFDKI@O NINDUOBG
F
KI@ONHW HNNDVIUHDNRKONDLHB VHRHDNKONDRIFO RIRKONDRB]OONKONUHBO@K@DMI@ MHDONO]KHORK@XBDEOK@XBDEHIKK]IFUXRKUS UOBGND@DKX
K
JI@XBO@@JO@HIJODRXRJGD]HDNXWJDO@HRJD[DJ UGO]IKNDRUHB
J
@IMD]IUDH]O RXLMHDUOB@UJFI]LI@_NKHNNDV
@
LIN]DR UGO]ISO_UHBRLI_NI JOI UOBGND@DKHORLOEHIN UOBGND@DKHORLOEHU RILOERONHBLOHDKONHWLO@@HUOBGLOUIMD@HB OWS@D]O]LOUIM]IHN ]OROI]BGLOUHR MHDUOBGND@DKHORLHNLIWLOEHBI@
L
NINDMHDUHW R.I.NINDLOERXNNIUONBISRNIU_]I@SGINIU_]ILD@ONODVIBRNO_]DNIWNHBDWNDJIENDRDSGI]LNDVIBXUNDVIEHRBDVO]XNDVDUOBN_U]HI@XR LOEHBI@N_U]HUHDN
N
S@_KLOE GOI]USD@XS@_R U]INRFOBUHDNSDWO@S]ORMOIRXS]HLIEHIKS]DUNOUODLHWS]DVONBO UOBGND@DKHOR RIRSW+UGO]ISO_UHBR
BI]@HNI UOBGND@DKHORBI]LIU RIBIX@IHNVHVDKONBO@ONXRBO@@OBUHRBO]ONHR UGO]ISO_UHBRBH@DIBD@BDLBDNHEHIB]DRRAOBUBXMO]NINDBXUGO]HRBXUDD BO@@ I]BGHUOBUR
BXUDRHI@ MHDLOEHB
B
EI VD@UO]]IEMV UOBGND@DKHOREOHNDVOEONE]HREONE]HUHBREHIFH]EHI@SGIEHIWGDNHUENI UGO]ISO_UHBREDLIHN UGO]ISO_UHBREDRHRDFU
GOLI]HNIGHRUI@HLGD]_R SGI]LIGXM]HKONHBR
G
Y_INU_L KONDLHBRY
]MNIND]EMHDUOBG]NUOBG F]INBO]DDU @HNOR UOBGND@DKX
]
RBINO@HRRB]OONBO@@RO@OWO@RONRD]HDNRHRONORJ_@EUOBGRS@HBDR
RUOLBHRR_]KHVHRHDRXNISBO@@ RIRRXNS]DRHR
R
UI]KODNUMF, KONHO UHRR_@IH]OUGO]IB@HDNUGO]IEHIKUGO]IVOBUXRU]INRKONOU]DSGDRUWBO@@
U
HEMHDHELXJHLIWHDHLL_UOSHN BO@@ I]UHNEHBHI MHDUOBGND@DKXHNNIUO SGI]LIHNNDMHDBGHSRHNNDSRXRHNNDVIUHVO GOI@UG EHIKNDRUHBRHNUOK]IKON RIHNVOBUXR
H
DNBDEORHKNDNBDLOEHBRD]HMIRO SGI]LIDU]2
D
SGI]LI@OIERSGI]NOWUSGO]OBXEOR SGI]LISGX@DKONOSGXRHJ]DNSGXRHDRUHLSHBDU[HRUSH@DRBHONBORS@INU IEVINBOEUOBGND@DKHOR SIU
S
VIWDN MHDUOBGVOWHL RIVH]DWHRVHUILFO]DVHVI@HRVDWBIN
V
[HUUXBO@@
[
WONUOBG
W
Now pirthbhpints
@HRU DF 976 BDLSINHOR SI]UHBHSIUHNK HN UGO RU_EX
22
http://www.aabam.com/http://abcell-bio.com/http://www.adnid.fr/http://www.adocia.com/http://www.a-biodesign.com/tag/advanced-biodesignhttp://www.affichem.fr/http://www.affilogic.com/http://www.aguettant.com/http://www.alaxia-pharma.eu/http://www.algenics.fr/http://www.alz-pharma.com/http://www.alzprotect.com/http://www.amarokbiotech.com/http://www.anacondapharma.com/http://www.animascope.eu/http://www.ans-biotech.com/http://www.antagene.com/http://aptys-pharmaceuticals.com/http://www.archimmed.com/http://www.atlangram.com/http://www.atlantic-bone-screen.com/FR/http://www.pasteur.fr/ip/easysite/pasteur/fr/relations-industrielles/start-uphttp://www.axoscience.com/http://www.b-cell-design.com/http://www.bioalliancepharma.com/http://www.bioalternatives.com/http://www.biocytex.fr/http://www.biogalenys.com/http://www.biogemma.com/http://www.biometiss.com/http://www.biomup.com/http://www.biophytis.com/http://www.biosentec.fr/http://www.biotrial.com/http://www.bioviron.fr/http://www.eye-brain.com/ebrainv5/index.php?lang=enhttp://www.effimune.com/http://www.enterome.com/http://www.erytech.com/http://www.eukarys.com/http://www.fermentalg.com/http://www.flamel.com/http://www.flowgene.com/http://www.fluigent.com/http://www.fluofarma.com/http://www.fluoptics.com/http://www.fogalebiotech.com/http://www.galenix.fr/http://www.genomicvision.com/http://www.genosafe.com/http://www.genoscreen.com/http://www.genticel.com/http://www.global-bioenergies.com/index.php?lang=frhttp://www.glycode.fr/http://www.glycodiag.com/http://www.graftys.com/http://www.gtptech.com/http://www.kaly-cell.com/http://www.kelia-pharma.com/http://www.keosys.com/http://www.khorionyx.com/http://www.koelis.com/http://www.kowok-theragnostic.com/http://www.symbiotec.fr/http://www.ltkfarma.com/http://www.lunginnov.com/http://www.manros-therapeutics.com/en/http://www.maunakeatech.com/http://www.mediantechnologies.com/http://www.medit.fr/http://www.medsenic.com/http://www.meiogenix.com/http://www.mellitech.com/http://www.metabolic-explorer.com/http://www.metabrainresearch.com/http://www.metis-biotech.com/http://www.minmaxmedical.com/http://www.nanobiotix.com/http://www.transferts-lr.org/transferts_lr/recherche_publique_en_region/actualites/partenariats_entreprises_recherche/nanomedsyn_une_start_up_dans_le_domaine_de_la_sante_creee_a_l_ibmm_institut_des_biomolecules_max_mousseronhttp://www.premice-bourgogne.com/fichiers/contenu_fichiers1/1080/Yves%20WACHE.pdfhttp://www.naturalpha.com/http://www.naturamole.com/http://www.neovacs.com/http://www.neuronax.com/http://www.nicox.com/http://www.nokad-pharma.com/http://www.nosopharm.com/http://www.novacyt.com/http://www.novadiscovery.fr/http://www.novotec-labs.com/http://www.nutrialys.fr/http://www.nutrialys.fr/http://www.plugmed.com/http://www.polyplus-transfection.com/http://www.poxel.com/http://www.crealys.com/portfolio_item/presbeasy/http://www.primadiag.com/http://www.protneteomix.com/http://www.provetech.com/http://www.px-therapeutics.com/http://www.carlinatech.com/http://www.carmatsa.com/http://www.invivogen.com/http://www.celenys.com/http://www.cellectis.com/http://www.cerenis.com/http://www.ciloa.fr/http://www.colcom.eu/http://www.conidia.fr/http://www.crossject.com/http://www.cybernano.eu/http://www.cytheris.com/http://www.cytoo.com/http://www.cytosial.com/http://www.davolterra.com/http://www.dbv-technologies.com/http://www.deinove.com/http://www.dendris.fr/http://www.dendritics.net/http://www.diafir.com/http://www.dialpha.com/http://www.diaxonhit.com/http://www.dna-therapeutics.com/http://www.domaintherapeutics.com/http://www.dosisoft.com/http://www.hemarina.com/http://www.histalim.com/http://www.horus-pharma.com/http://www.hybrigenics.com/http://www.quantum-genomics.com/http://www.rbnano.fr/http://www.rd-biotech.com/http://www.rntech.com/http://www.rootlines-tech.com/http://www.scanelis.com/http://www.screencell.com/http://www.selexel.com/http://www.sensorion-pharma.com/http://www.sisene.com/http://www.skuldtech.com/http://www.splicos.com/http://www.stemcis.com/http://www.surgivisio.com/http://www.synapcell.com/http://www.synprosis.com/http://www.tbf-lab.com/index.htmlhttp://www.theraclion.com/http://www.theradiag.com/http://www.theravectys.com/http://www.transgene.fr/http://www.trophos.com/http://www.txcell.com/http://www.idbio.eu/http://www.idmyk.com/http://www.imaxio.com/http://www.immutep.com/http://www.incellart.com/http://www.indicia.fr/http://www.innate-pharma.com/http://www.innobiochips.fr/http://www.innopsys.com/http://www.ihdiag.com/http://www.integragen.com/http://www.invectys.com/http://www.oncodesign.fr/http://www.oncomedics.com/http://www.oribase-pharma.com/http://www.otr3.com/http://www.pharmaleads.com/http://www.pharnext.com/http://fr.pherecydes-pharma.com/http://www.phylogene.com/http://www.physikron.com/http://www.physiostim.com/http://www.picotwist.com/http://www.pilosciences.com/http://www.plantadvanced.com/http://www.plantadvanced.com/http://www.vaxon-biotech.com/http://www.vexim.com/http://www.viroxis.com/http://www.vitamfero.com/http://www.vivalis.com/http://www.voxcan.fr/http://www.wittycell.com/http://www.xentech.eu/http://abcell-bio.com/http://www.xentech.eu/http://www.wittycell.com/http://www.voxcan.fr/http://www.vivalis.com/http://www.vitamfero.com/http://www.viroxis.com/http://www.vexim.com/http://www.vaxon-biotech.com/http://www.txcell.com/http://www.trophos.com/http://www.transgene.fr/http://www.theravectys.com/http://www.theradiag.com/http://www.theraclion.com/http://www.tbf-lab.com/index.htmlhttp://www.synprosis.com/http://www.synapcell.com/http://www.surgivisio.com/http://www.stemcis.com/http://www.splicos.com/http://www.skuldtech.com/http://www.sisene.com/http://www.sensorion-pharma.com/http://www.selexel.com/http://www.screencell.com/http://www.scanelis.com/http://www.rootlines-tech.com/http://www.rntech.com/http://www.rd-biotech.com/http://www.rbnano.fr/http://www.quantum-genomics.com/http://www.px-therapeutics.com/http://www.provetech.com/http://www.protneteomix.com/http://www.primadiag.com/http://www.crealys.com/portfolio_item/presbeasy/http://www.poxel.com/http://www.polyplus-transfection.com/http://www.plugmed.com/http://www.plantadvanced.com/http://www.pilosciences.com/http://www.picotwist.com/http://www.physiostim.com/http://www.physikron.com/http://www.phylogene.com/http://fr.pherecydes-pharma.com/http://www.pharnext.com/http://www.pharmaleads.com/http://www.otr3.com/http://www.oribase-pharma.com/http://www.oncomedics.com/http://www.oncodesign.fr/http://www.nutrialys.fr/http://www.novotec-labs.com/http://www.novadiscovery.fr/http://www.novacyt.com/http://www.nosopharm.com/http://www.nokad-pharma.com/http://www.nicox.com/http://www.neuronax.com/http://www.neovacs.com/http://www.naturamole.com/http://www.naturalpha.com/http://www.premice-bourgogne.com/fichiers/contenu_fichiers1/1080/Yves%20WACHE.pdfhttp://www.transferts-lr.org/transferts_lr/recherche_publique_en_region/actualites/partenariats_entreprises_recherche/nanomedsyn_une_start_up_dans_le_domaine_de_la_sante_creee_a_l_ibmm_institut_des_biomolecules_max_mousseronhttp://www.nanobiotix.com/http://www.minmaxmedical.com/http://www.metis-biotech.com/http://www.metabrainresearch.com/http://www.metabolic-explorer.com/http://www.mellitech.com/http://www.meiogenix.com/http://www.medsenic.com/http://www.medit.fr/http://www.mediantechnologies.com/http://www.maunakeatech.com/http://www.manros-therapeutics.com/en/http://www.lunginnov.com/http://www.ltkfarma.com/http://www.symbiotec.fr/http://www.kowok-theragnostic.com/http://www.koelis.com/http://www.khorionyx.com/http://www.keosys.com/http://www.kelia-pharma.com/http://www.kaly-cell.com/http://www.invectys.com/http://www.integragen.com/http://www.ihdiag.com/http://www.innopsys.com/http://www.innobiochips.fr/http://www.innate-pharma.com/http://www.indicia.fr/http://www.incellart.com/http://www.immutep.com/http://www.imaxio.com/http://www.idmyk.com/http://www.idbio.eu/http://www.hybrigenics.com/http://www.horus-pharma.com/http://www.histalim.com/http://www.hemarina.com/http://www.gtptech.com/http://www.graftys.com/http://www.glycodiag.com/http://www.glycode.fr/http://www.global-bioenergies.com/index.php?lang=frhttp://www.genticel.com/http://www.genoscreen.com/http://www.genosafe.com/http://www.genomicvision.com/http://www.galenix.fr/http://www.fogalebiotech.com/http://www.fluoptics.com/http://www.fluofarma.com/http://www.fluigent.com/http://www.flowgene.com/http://www.flamel.com/http://www.fermentalg.com/http://www.eukarys.com/http://www.erytech.com/http://www.enterome.com/http://www.effimune.com/http://www.eye-brain.com/ebrainv5/index.php?lang=enhttp://www.dosisoft.com/http://www.domaintherapeutics.com/http://www.dna-therapeutics.com/http://www.diaxonhit.com/http://www.dialpha.com/http://www.diafir.com/http://www.dendritics.net/http://www.dendris.fr/http://www.deinove.com/http://www.dbv-technologies.com/http://www.davolterra.com/http://www.cytosial.com/http://www.cytoo.com/http://www.cytheris.com/http://www.cybernano.eu/http://www.crossject.com/http://www.conidia.fr/http://www.colcom.eu/http://www.ciloa.fr/http://www.cerenis.com/http://www.cellectis.com/http://www.celenys.com/http://www.invivogen.com/http://www.carmatsa.com/http://www.carlinatech.com/http://www.bioviron.fr/http://www.biotrial.com/http://www.biosentec.fr/http://www.biophytis.com/http://www.biomup.com/http://www.biometiss.com/http://www.biogemma.com/http://www.biogalenys.com/http://www.biocytex.fr/http://www.bioalternatives.com/http://www.bioalliancepharma.com/http://www.b-cell-design.com/http://www.axoscience.com/http://www.pasteur.fr/ip/easysite/pasteur/fr/relations-industrielles/start-uphttp://www.atlantic-bone-screen.com/FR/http://www.atlangram.com/http://www.archimmed.com/http://aptys-pharmaceuticals.com/http://www.antagene.com/http://www.ans-biotech.com/http://www.animascope.eu/http://www.anacondapharma.com/http://www.amarokbiotech.com/http://www.alzprotect.com/http://www.alz-pharma.com/http://www.algenics.fr/http://www.alaxia-pharma.eu/http://www.aguettant.com/http://www.affilogic.com/http://www.affichem.fr/http://www.a-biodesign.com/tag/advanced-biodesignhttp://www.adocia.com/http://www.adnid.fr/http://www.aabam.com/ -
7/23/2019 Etude 2012-VInteractive FranceBiotech
33/35
25
Oxghmht Hneox
9
=
2
5
?
6
;
7
8
93
99
9=
92
95
9?
96
9;
97
98
=3
=9
==
=2
Ovd`uthdn df @hfo Rbhonbos Bdlpiny Broithdn hn Frinbo 3;
Nulmor df olp`dyoos 93
@ovo` df Oeubithdn Ibghovoe my Olp`dyoos 93
Bdlpinhos my iko 99
Drhkhn df tgo bdlpiny 99
Edlihn df Ibthvhty 99
Bdlpinhos broitoe dr `hquheitoe hn =39= 9=
Ehstrhmuthdn df Sirtnorsghp Uypos 95
Ehstrhmuthdn df B`honts my Hneustry Robtdr 95
Sitont Ipp`hbithdns 96
Sitonts ]obohvoe 96
Sitonts Oxp`dhtoe 96
Ugoripouthb Srdeubts my Fdbus Iroi 97
Ugoripouthb Srdeubts my Rtiko df Eovo`dplont 97
Ehikndsthb Srdeubts my Fdbus Iroi 98
Ovd`uthdn df @hfo Rbhonbos Hneustry Funehnk =3
Ovd`uthdn df Fronbg @hfo Rbhonbos HSDs dn NXRO Ourdnoxt =3
Ehstrhmuthdn df VB Funehnk =9
Xdunk Hnndvithvo Ontorprhso Rtitus 'AOH( ==
@hfo Rbhonbos HSD Funerihshnk my Bduntr y1 NXRO Ourdnoxt ine I`tornoxt =6
Lirjot Biphti`hzithdns my Bduntry1 NXRO Ourdnoxt ine I`tornoxt Mhdtobgnd`dky
ine Loehbi` Oquhplont Bdlpinhos =6
NXRO NOWU Mhdtobg Hneox =;
Bdlpirhsdn df VB Fhninbhnk hn Ourdpoin @hfo Rbhonbos1 =337=39= =8
-
7/23/2019 Etude 2012-VInteractive FranceBiotech
34/35
BroehtsSgdtds 1 Fdtd`hiIrthsthb Ehrobthdn 1 S`us quo `os ldts
Imdut Frinbo MhdtobgFrinbo Mhdtobg hs tgo issdbhithdn df Fronbg bdlpinhos hn tgo @hfo Rbhonbos sobtdr inetgohr pirtnors. Hts lhsshdn hs td bdntrhmuto td edlosthb krdwtg hn tghs hnndvithvo hneustryine td suppdrt Frinbos `oieorsghp rd`o whtghn tgo Ourdpoin @hfo Rbhonbos bdllunhty.Ldro spobhfhbi``y, Frinbo Mhdtobg ibts is in onkhno df bginko my hntoribthnk whtg tgokdvornlont, obdndlhb drkinhzithdns, ibieolhb hnsthtuthdns, tgo loehi ine tgo hnvostdrbdllunhty td onsuro tgo prhdrhthzithdn df tgo @hfo Rbhonbos sobtdr hn Frinbo ine tgohlprdvolont df tgo obdndlhb, `oki`, roku`itdry ine linikorhi` onvhrdnlonts fdr tghshlpdrtint hneustry.
Broitoe hn 988;, Frinbo Mhdtobg unhtos tgo oieors df hnndvithvo @hfo Rbhonbos bdlpinhoswhtg tgohr pirtnors hn tgo hnvostlont, `oki` ine ibieolhb fho`es. Lolmors bdlo frdl i``dvor Frinbo ine roprosont oibg fho`e df tgo @hfo Rbhonbos 'mhdtobgnd`dky, loehbi` tobgnd`dky, b`oin$kroon tobgnd`dky(. _neor tgo minnor df Frinbo Mhdtobg, tgoso hneustry`oieors fhkgt td broito i now ldeo` df ontropronoursghp hn Frinbo ine td suppdrt tgobroithdn df bdlpinhos ine adms hn tghs hnndvithvo sobtdr. @oe my Iner Bgdu`hji shnbo=338, Frinbo Mhdtobg bdnthnuos td sd`hbht pum`hb pdwors, obdndlhb eobhshdn lijors inetgo loehi dn mogi`f df ibtdrs hn tgo Fronbg @hfo Rbhonbos.
Sindrili RtueyRhnbo =33=, Frinbo Mhdtobg gis bdneubtoe tgo Sindrili df tgo @hfo Rbhonbos Hneustryhn Frinbo, i unhquo stuey tgit prdvheos in innui` upeito dn tgo krdwtg ine eynilhsldf tghs hnndvithvo sobtdr hn Frinbo. Ugo rosu`ts df tghs stuey i``dw Frinbo Mhdtobg td krdune
hts prdpdsi`s td tgo kdvornlont hn gire fibts ine td offobthvo`y roprosont tgo onthrohneustry. Ugo Sindrili ini`ysos eiti frdl hneoponeont bdlpinhos i``dbithnk it `oist9?/ df tdti` sponehnk td ]osoirbg ine Eovo`dplont bdsts. Frinbo Mhdtobg survoyoeldro tgin 533 bdlpinhos vhi i soburo dn`hno quosthdnnihro ine gis ini`yzoe tgo eitiprdvheoe frdl 976 df tgo 98= tdti` rospdnsos. Ugo rosu`ts df tghs sur voy wh`` rolihn tgoprdporty df Frinbo Mhdtobg.
Giueo Bdsti
Konori` RobrotiryFrinbo Mhdtobg
Mondt Mrdbire
Srdaobt LinikorFrinbo Mhdtobg
Edlhnhquo ]onburo`
SirtnorDrjds Biphti`
Vhrkhnho Fdntihno
Hnndvithdn OxportDROD
Sh`dt Bdllhttoo
Berhb Kuh``orlo
Srdaobt @oieor,Mhdtobgnd`dkyEKBHR
Bgigri @duifh
Hnvostlont Ehrobtdrit BEB Ontroprhsos
Shorro Rdr`hor
Srdaobt @oieor,Lhnhstry fdrHneustrhi` ]onowi`EKBHR
Ehsb`ihlor
I`tgdukg dur most offdrts woro khvon td issurhnk tgo ibburiby inebdlp`otonoss df tgo hnfdrlithdn prdvheoe hn tghs ropdrt, ht hs pdsshm`otgit bortihn eotih`s givo osbipoe dur ndthbo. S`oiso shkni` iny orrdrsdr dlhsshdns my olih`hnkbdntibtCfrinbomhdtobg.drk
http://localhost/var/www/apps/conversion/tmp/scratch_3/[email protected]://localhost/var/www/apps/conversion/tmp/scratch_3/[email protected] -
7/23/2019 Etude 2012-VInteractive FranceBiotech
35/35
Frinbo Mhdtobg2$? H ] h``